Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

MBIO vs ABVE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBIO Captures Overall Composite Edge (42.9 HOLD vs 39.8 SELL), While ABVE Leads 5–1 on Growth & Valuation Pillars

MBIO Overall Winner 6-Pillar Tally: MBIO 1 – 5 ABVE Matrix Metrics: MBIO 6 – 2 ABVE

As of Nov 17, 2026, Mustang Bio, Inc. (MBIO) captures the overall head-to-head institutional edge over Above Food Ingredients Inc. (ABVE) on higher Unified Composite conviction (42.9/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality), while ABVE wins 5–1 across the 6-pillar growth and valuation breakdown. MBIO trades at $0.39 (N/M Forward P/E, 0.0% operating margin) versus ABVE at $0.11 (N/M Forward P/E, -23.2% operating margin).

  • Growth vs. Quality Trade-Off: MBIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. ABVE 39.8/100 SELL) and 0.68β · 87% Vol risk profile, whereas ABVE leads top-line expansion (-45.0% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile ABVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBIO vs ABVE
MBIO NASDAQ Head-to-Head Winner
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.68β · 87% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $0.40 · SMA50: $0.44
ABVE NASDAQ
Above Food Ingredients Inc. Common Stock
Food And Kindred Products
$0.11
-80.57% 1D
Market Cap $30.0M
TTM Revenue $295M
Forward P/E N/M
Beta / 30D Vol 4.10β · 310% Vol
Unified Composite Score
39.8 / 100 SELL
Tech 40.0 Fund 47.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.1%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $0.55 · SMA50: $0.67

6-Pillar Scorecard Institutional Category Breakdown (MBIO 1 – 5 ABVE)

Columns: Metric · MBIO · ABVE
1. Valuation Multiples ABVE
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.1x
2. Growth & Scale ABVE
Revenue Growth (YoY) +0.0% -45.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $295M
Market Cap $3.2M $30.0M
3. Profitability & Quality MBIO
Gross Margin N/A -2.8%
Operating Margin 0.0% -23.2%
Net Profit Margin 0.0% -23.4%
Return on Equity (ROE) -43.1% 0.0%
4. Balance Sheet & Cash Flow ABVE
Cash Generation (TTM) N/A -$40M EBITDA
Cash Flow Margin N/A -13.7% EBITDA Mgn
Net Cash / Leverage $0.87 Book/Sh · -43.1% ROE 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVE
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 148.3% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ABVE
OpEx & R&D Intensity N/A 20.4% of Rev ($60M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBIO (6) vs ABVE (2)
Institutional Metric MBIO ABVE Criterion Row Edge
Market Capitalization
Scale
$3.2M $30.0M Larger Scale ABVE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -45.0% Higher Growth MBIO
Operating Margin (TTM)
Profitability
0.0% -23.2% Higher Margin MBIO
Net Profit Margin
Profitability
0.0% -23.4% Higher Margin MBIO
Return on Equity (ROE)
Capital Efficiency
-43.1% 0.0% Higher ROE ABVE
52-Week Range Position
Momentum
3% ($0–$1) 0% ($0–$7) Stronger Trend MBIO
Beta / 30D Volatility
Risk Regime
0.68β · 87% Vol 4.10β · 310% Vol Lower Realized Risk MBIO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 39.8 / 100 (SELL) Higher Composite MBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $295M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -2.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.87 Book/Sh · -43.1% ROE) -$40M EBITDA (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBIO +82.96 pp
MBIO: +3.78% · ABVE: -79.18%
3M Horizon MBIO +71.75 pp
MBIO: -19.68% · ABVE: -91.43%
6M Horizon MBIO +57.69 pp
MBIO: -37.98% · ABVE: -95.67%
1Y Horizon MBIO +57.8 pp
MBIO: -36.97% · ABVE: -94.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs ABVE. Trailing 12-month operating profitability (MBIO 0.0% vs ABVE -23.2%) and valuation multiples (MBIO N/M vs ABVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.1% · N/M
ABVE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$295M
Gross Margin-2.8%
Op. Margin-23.2%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 148.3%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABVE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVE Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $30.0M market capitalization and -23.2% operating margin.
OpEx & R&D Reinvestment 20.4% of Rev ($60M)
90D Engineering Disclosures 0 Published

Investor FAQ MBIO vs ABVE Key Questions & Quantitative Answers

As of Nov 17, 2026, Mustang Bio, Inc. (MBIO) captures the overall head-to-head institutional edge over Above Food Ingredients Inc. (ABVE) on higher Unified Composite conviction (42.9/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality), while ABVE wins 5–1 across the 6-pillar growth and valuation breakdown. MBIO trades at $0.39 (N/M Forward P/E, 0.0% operating margin) versus ABVE at $0.11 (N/M Forward P/E, -23.2% operating margin). Growth vs. Quality Trade-Off: MBIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. ABVE 39.8/100 SELL) and 0.68β · 87% Vol risk profile, whereas ABVE leads top-line expansion (-45.0% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile ABVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVE leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABVE at -45.0% YoY revenue growth and +0.0% YoY earnings growth on $295M TTM revenue (-2.8% gross margin, -23.2% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $295M for ABVE. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus 20.4% of Rev ($60M) (0 disclosures) for ABVE.

ABVE screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus ABVE (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 87% Vol realized risk). By comparison, ABVE carries 148.3% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 310% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.